- Research article
- Open Access
Mathematical model of uptake and metabolism of arsenic(III) in human hepatocytes - Incorporation of cellular antioxidant response and threshold-dependent behavior
© Stamatelos et al; licensee BioMed Central Ltd. 2011
- Received: 16 February 2010
- Accepted: 25 January 2011
- Published: 25 January 2011
Arsenic is an environmental pollutant, potent human toxicant, and oxidative stress agent with a multiplicity of health effects associated with both acute and chronic exposures. A semi-mechanistic cellular-level toxicokinetic (TK) model was developed in order to describe the uptake, biotransformation and clearance of arsenical species in human hepatocytes. Notable features of this model are the incorporation of arsenic-glutathione complex formation and a "switch-like" formulation to describe the antioxidant response of hepatocytes to arsenic exposure.
The cellular-level TK model applies mass action kinetics in order to predict the concentrations of trivalent and pentavalent arsenicals in hepatocytes. The model simulates uptake of arsenite (iAsIII) via aquaporin isozymes 9 (AQP9s), glutathione (GSH) conjugation, methylation by arsenic methyltransferase (AS3MT), efflux through multidrug resistant proteins (MRPs) and the induced antioxidant response via thioredoxin reductase (TR) activity. The model was parameterized by optimization of model estimates for arsenite (iAsIII), monomethylated (MMA) and dimethylated (DMA) arsenicals concentrations with time-course experimental data in human hepatocytes for a time span of 48 hours, and dose-response data at 24 hours for a range of arsenite concentrations from 0.1 to 10 μM. Global sensitivity analysis of the model showed that at low doses the transport parameters had a dominant role, whereas at higher doses the biotransformation parameters were the most significant. A parametric comparison of the TK model with an analogous model developed for rat hepatocytes from the literature demonstrated that the biotransformation of arsenite (e.g. GSH conjugation) has a large role in explaining the variation in methylation between rats and humans.
The cellular-level TK model captures the temporal modes of arsenical accumulation in human hepatocytes. It highlighted the key biological processes that influence arsenic metabolism by explicitly modelling the metabolic network of GSH-adducts formation. The parametric comparison with the TK model developed for rats suggests that the variability in GSH conjugation could have an important role in inter-species variability of arsenical methylation. The TK model can be incorporated into larger-scale physiologically based toxicokinetic (PBTK) models of arsenic for improving the estimates of PBTK model parameters.
- Human Hepatocyte
- Methylation Reaction
- Arsenic Metabolism
Arsenic is a naturally occurring metalloid, abundant in the earth's crust and a component of more than 245 minerals . Exposure to arsenic has been associated with cancers of the liver, bladder, skin and lung [2, 3]. Epidemiological studies in Taiwan, Bangladesh and India have reported adverse health effects associated with chronic arsenic exposure including; chronic obstructive pulmonary disease, non-cirrhotic portal fibrosis, hypertension and ischeamic heart disease . The risk of developing serious diseases from chronic exposure to inorganic arsenic in drinking water prompted the US Environmental Protection Agency (EPA) to lower the maximum contamination level (MCL) for arsenic in drinking water to 10 ppb .
There are two biologically important arsenic valence states: arsenite (As(OH)3, iAsIII) and arsenate (AsO(OH)3, iAsV). Inorganic arsenic in water is largely in the form of arsenate; it is negatively charged at physiological pH and slowly taken up by cells . Arsenate is rapidly converted to arsenite in vivo  which is taken up by cells much more quickly than arsenate . Methylation of arsenicals facilitates their excretion from the cell and therefore was long considered a detoxification process, but recent evidence indicates that monomethylated (MMA) and dimethylated (DMA) arsenicals have many toxic effects including increased oxidative stress , chromosomal aberrations (CA), and oxidative DNA damage [10–12]. In hepatocytes, trivalent monomethylated arsenicals (MMAIII) inhibit the activity of thioredoxin reductase (TR), which is a critical antioxidant enzyme controlling the cellular redox balance [13, 14].
Uptake and efflux of arsenicals occur primarily through transporter proteins. Uptake of iAsIII in hepatocytes and efflux of MMAIII to blood take place through aquaporin isozymes 9 (AQP9), a family of membrane-spanning proteins that facilitate movement of solutes down their concentration gradient. AQP9 channels are expressed at high concentrations in liver cells and have been shown to transport iAsIII when expressed both in Saccharomyces cerevisiae (yeast) and in Xenopus oocytes [15–17]. Another class of transmembrane proteins facilitating the transport of iAsIII and MMAIII across the cellular membrane of hepatocytes is glucose transporters and especially GLUT2 which is highly expressed in the liver [18, 19]. Glutathione conjugated arsenicals are exported to the extracellular space via multidrug resistant proteins (MRPs) and multidrug resistant P-glycoproteins (PGPs)which are ATP-binding cassette (ABC) transporters that export solutes against their concentration gradient [19–21].
Methylation of inorganic arsenic takes place primarily in the liver and specifically in hepatocytes via enzymatic catalysis by arsenic methyltransferase (AS3MT), previously known as Cyt19, producing both mono- and dimethylated arsenicals [22–25]. Two biochemical pathways have been proposed for methylation of arsenates with a key difference in the substrate for AS3MT methylation: (a) a classical process of alternating steps of reduction and oxidative methylation where iAsIII and MMAIII are the substrates and the methylation can happen in the presence or absence of GSH  and (b) a process of GSH conjugation and reductive methylation where thiol-bound arsenicals (arsenic triglutathione - ATG, monomethylarsenic diglutathione - MADG) are the substrates [27, 28]. GSH has a stimulatory role in both methylation pathways either as a reductant or in direct conjugation with arsenicals .
Arsenic activates the redox sensitive transcription factor Nuclear Factor -E2- related factor 2 (Nrf2) causing its increased nuclear translocation and Nrf2 binding to the Antioxidant Response Element (ARE) [30, 31]. Arsenic activates Nrf2 in a different manner when compared to other compounds such as sulforaphane (SF) and tert-butylhydroquinone (tBHQ) enhancing the interaction of specific subunits of the E3 ubiquitin ligase . It has been suggested that hepatocytes exhibit an "on-switch" antioxidant behavior when exposed to increasing arsenic doses , possibly a result of this Nrf2 activation.
The human TK model applies mass action kinetics in order to predict the concentrations of trivalent and pentavalent arsenicals including arsenite (iAsIII), monomethylated (MMA), and dimethylated arsenicals (DMA) in human hepatocytes. This TK model takes into account processes such as influx, efflux, methylation, oxidation and glutathione conjugation of arsenicals. Moreover, it accounts for induced cellular antioxidant response due to arsenic exposure through a "switch-like" mechanism that alters the model response above a specific threshold concentration .
This model has been compared with the Easterling et al. model  , in terms of the ability to fit to data of arsenic retention and methylation in human hepatocytes. This comparison aims to highlight the advantages of developing biologically relevant TK models based on data acquired from human cells. Further comparison of these two models in terms of their estimated parameter values aim to study the major intracellular kinetic processes that contribute to the differences in metabolism between humans and rats.
Optimized parameter values of the TK model along with the corresponding process they describe
Rate of production of ATG
Rate of production of MADG
Rate of production of DMAG
Rate of oxidation of DMAIII
Rate of oxidation of MMAIII
Rate of production of iAsIII
Rate of production of MMAIII
Hill coefficient of inhibition of MMAIII production
Dissociation constant of inhibition of MMAIII
Coefficient of inhibition of MADG hydrolysis
Rate of GSH production increase
Rate of production of DMAIII
Coefficient of inhibition of DMAG hydrolysis
Maximal rate of MADG efflux
Half saturation constant of MADG efflux
Rate of upregulation of MRP
Steady state rate of efflux of iAsIII
Time constant of AQP9 inactivation
Initial rate of efflux of iAsIII
Influx of iAsIII
Rate of efflux of MMA
Coefficient of efflux of MMA
Maximal rate of ATG efflux
Half saturation constant of ATG efflux
Rate of efflux of DMA
Coefficient of efflux of DMA
Maximal rate of ATG methylation
Half saturation constant of ATG methylation
Hill coefficient of ATG methylation
Dissociation constant of ATG methylation
Inhibition constant of ATG methylation
Inhibition constant of MADG methylation
Maximal rate of MADG methylation
Half saturation constant of MADG methylation
Hill coefficient of MADG methylation
Dissociation constant of MADG methylation
Rate of AS3MT efficiency increase
Coefficient of MADG methylation inactivation
Rate of TR signaling
Rate of TR inactivation
Constant of TR inactivation
Hill coefficient of TR inactivation
Steady state value of TR activity
Arsenite influx across the cellular membrane pores is governed by their electrochemical potential, and can be described through an ion channel conductance-based formulation.
The oxidative stress mediated response of hepatocytes to arsenite exposure exhibits a "switch-like" behavior, and the upregulation of enzyme activities can be described through an approximate step function at a threshold concentration.
The methylation reactions are influenced by cooperativity phenomena as well as substrate inhibition, and can be described through a hybrid approach of Hill and Michaelis-Menten kinetics.
The GSH-bound hydrolysis and clearance of methylated arsenicals exhibit a threshold-dependent behavior, and can be described using a sigmoidal function.
Concentrations of arsenicals are uniform within the hepatocytes as well as the extracellular medium
All hepatocytes in the system have identical properties, are uniformly distributed in the medium, and are exposed to the same extracellular concentrations of arsenicals.
Where, kinf represents the mass transfer coefficient for influx of arsenite in hepatocytes; represents the rate constant for arsenite conjugation with GSH to form ATG catalyzed by the Glutathione S-Transferase (GST) family of enzymes; is the rate constant for hydrolysis of ATG (reciprocal to conjugation); kSS is the steady state rate constant for efflux of arsenite that is attained at long time periods; k0 is the rate constant describing the basal activity of AQP9; and τe is the time constant governing the regulation of AQP9 gates.
where, kTR is the first-order rate constant controlling the activity of TR; TR0 is the baseline activity value of TR; is the first-order rate constant for TR inactivation; TRc is a dimensionless inactivation constant; N is the Hill coefficient for enzyme inactivation from MMAIII; , and are the rate constants governing of the activities of GSH, MRP and AS3MT, , and are the corresponding first-order decay constants.
Methylation reactions of arsenic in the liver have been modeled in published cellular-level and whole-body PBTK models with classical Michaelis-Menten kinetics [34, 44–46]. Alternatives include cooperativity models such as the classical Hill-type formulation and the more mechanistic Monod-Wyman-Changeux (MWC) model . In preliminary analyses, these formulations were unable to explain the time course patterns of arsenic retention and methylation in human hepatocytes (results not shown). Therefore, an alternative, non-classical formulation was used in the TK model. In this model, the AS3MT is assumed to exhibit cooperativity and the methylation reaction rate is assumed to exhibit hysteretic sigmoidal behavior as per Frieden . In this formulation, the cooperativity is described by a Hill-type formulation for Vmax that is dependent on the total ATG present in the system. The formulation accounts for the constitutive influence of GSH in the methylation reaction cascade and its role in the increase of Vmax. Moreover this Hill-type formulation for Vmax accounts for a possible colocalization of thiol-containing proteins that interact with GSH (e.g. GSTP1), MRPs and AS3MT in hepatocytes. This colocalization would control not only the production and clearance of ATG but methylation activity as well [49, 50].
where, MADGui and DMAGui are the rates of arsenic methylation for the first and second methylation reactions respectively. and are the maximal rates of the first and second methylation reactions respectively; and are the half-saturation constants for the methylation reactions; Kim and Kid are the uncompetitive inhibition constants for the respective reactions n1, n2 are the Hill coefficients; and are the dissociation constants influencing the sigmoidal change in and ; and fA is a coefficient of the second methylation reaction inactivation.
where HDm and HDd are the rates of hydrolysis of MADG and DMAG respectively. is the reaction rate constant for MADG hydrolysis (MMAIII production); is the coefficient of inhibition of MADG hydrolysis; n3 and are the Hill coefficient and dissociation constant, respectively, for the inhibition term; is the reaction rate constant for DMAG hydrolysis (DMAIII production); and is the coefficient of inhibition of DMAG hydrolysis.
where, and are the Michaelis constants of the biophysical clearance of ATG and MADG, respectively; and are the rate constants of MMA and DMA clearance, respectively; fm and fd are the dimensionless coefficients of clearance of the respective processes affecting the maximal efflux.
where is the rate constant of MADG production catalyzed by the Glutathione S-Transferase (GST) family of enzymes; koxm is the rate constant for MMAIII oxidation; kDMAG is the rate constant for DMAG production catalyzed by the Glutathione S-Transferase (GST) family of enzymes and koxd is the rate constant for DMAIII oxidation. It has been suggested for this biotransformation pathway that trivalent arsenicals mostly bound to thiol-containing proteins are conjugated with GSH and methylated in the presence of arsenic methyltransferase (AS3MT) . Therefore, the parameters kATGint, and kDMAG indirectly represent the binding of trivalent arsenicals to thiol-containing proteins in the TK model.
The TK model has been implemented in MATLAB; the system of ODEs comprising the TK model is solved numerically using the stiff solver ode15s. First, the model parameters corresponding to low doses (i.e. below the threshold) were estimated using time course in vitro measurements of arsenicals following exposures to 0.1 μM iAsIII , from Styblo et al. ; it was assumed that at this dose, the hepatocytes exhibit no induced antioxidant response. Subsequently, model parameters corresponding to a wider range of doses (i.e. including both low-dose and high-dose behavior) were estimated using dose-response data (for doses ranging from 0.1 - 10 μM) reported by Drobna et al. . The Drobna dataset includes measured concentrations of iAsIII, MMA, and DMA in primary cultured human hepatocytes after 24 h exposure to iAsIII (data for hepatocytes from 8 donors). For this case study, data on hepatocytes from one donor (white female, aged in the 60 s, Donor C)  were used, since this donor had similar characteristics to the human donor in the study by Styblo et al.  . The deterministic optimization function fmincon was used for parameter estimation in both cases.
where Y denotes model output and P denotes the vector of model parameters; DP and D illustrate the partial and total variance of the model output due to variation in model parameters according to assigned statistical distributions.
The model parameters were assumed to be normally distributed with a coefficient of variation up to 10%; for some parameters, the coefficient of variation was 1%. Ten thousand (10,000) samples were generated and the normal distributions for all parameters were truncated at 1% and 99% (approximately three standard deviations from the mean value). Three model outputs were selected for the sensitivity analysis: Areas under the Curve (AUCs) of total retention of MMA, DMA and iAsIII in human hepatocytes. The SIMLAB modeling platform  was used to perform the global sensitivity analysis.
Comparison with the TK modeling formulation for rat hepatocytes
Comparison of selected parameter values between two hepatocyte-level TK modeling formulations
Human-Hepatocyte TK model
Rat-Hepatocyte TK model
NP - iAsIII
NM - 1st Reaction (1/min)
NM - 2nd Reaction (1/min)
Biotransformation - 1st MRS
The time-course estimates from the TK model show that initially (within first minutes of exposure) the rate of influx of AQP9s is substantially higher than the metabolism, thus leading to a fast accumulation of arsenite inside the cells. Then, the influx is reduced, and metabolism increases, thus leading to a slow decrease in arsenite levels (till 8 to 9 hours). During this period, MMA production appears to be the dominant process, as shown by higher levels of MMA compared to DMA, attributable to the high rate of MADG hydrolysis. Subsequently, the arsenite concentrations decrease at a faster rate, the second methylation reaction becomes more significant, and MADG hydrolysis is inhibited (Equation 9).
Figure 7B shows sensitivity analysis results for intracellular DMA levels. Similar to results from sensitivity analysis of MMA levels (Figure 7A), the transport parameter k0 (Parameter 19) is the most influential parameter at low doses (0.1 μΜ). For 1 μM dose, DMA production is significantly influenced primarily by (Parameter 13), which affects the rate of DMAG hydrolysis. Furthermore, the oxidation reaction is not important in the case of DMA levels, because DMA transport across the cellular membrane is much faster compared to MMA transport . This is also corroborated by the relative values of corresponding transport parameters for MMA and DMA (fd >> fm,, as shown in Table 1), and by the findings of Styblo et al. .
Figure 7C shows sensitivity analysis results for intracellular iAsIII levels. At low doses (0.1 μΜ), the TSIs of most parameters are close to 1, indicating very high contributions. This unusual finding can be attributed to large interaction effects among multiple model parameters on the model output (i.e. binary interactions terms such as Dij,,and tertiary interaction terms such as Dijk). This was verified by computing first-order sensitivity indices, which account for contribution of each individual parameter (Di) to the output variance without taking into account higher-order interactions [57, 58]; these indices for all parameters were low (< 0.1) at low doses (results not shown). At higher doses, (Parameter 1) and (Parameter 6) are the most influential. Both these parameters correspond to rate constants in the bidirectional reaction of ATG with iAsIII (glutathione conjugation of arsenite and ATG hydrolysis).
A fundamental hypothesis in this modeling formulation that allows the capturing of the dose-response profiles of arsenic retention and methylation across doses (Figure 5), is the introduction of threshold-dependent non-linear ("switch-like") mechanisms in the metabolic network due to oxidative stress (TR inactivation). This assumption is based on findings that signaling motifs exhibit biological switches under a narrow range of endogenous or exogenous stimuli . This is often described by a Hill equation with a large Hill coefficient (e.g., kinase cascades  and nuclear-receptor pathways [61, 62]). The large Hill coefficient for inhibition of MADG hydrolysis (Table 1 - Parameter 8) points to potential "switch-like" behavior of the activation of Nrf2 due to arsenic-mediated oxidative stress .
The parametric comparison between human and rat hepatocyte TK models for arsenic, presented in Table 2, provides insight into factors that affect arsenic metabolism in hepatocytes. Specifically, the AS3MT activity is found to be not a significant factor. Rats have been reported to be much faster metabolizers of arsenic than humans , but based on this study this is attributed to other factors. Specifically, in the rat-hepatocyte TK model (Figure 1), the protein-bound arsenite (p-iAs) is biotransformed to iAs (substrate of methylation reaction) at a much higher rate (five orders of magnitude) compared to the biotransformation of iAsIII to ATG (substrate of methylation reaction) of the human-hepatocyte TK model (Figure 3). This variability could be influenced by polymorphisms related to GSH production in hepatocytes  or availability of thiol-containing proteins to interact with AS3MT .
This work demonstrates the development of a prototype semi-mechanistic toxicokinetic (TK) model for arsenicals in human hepatocytes introducing features such as cooperativity and "switch-like" antioxidant response. Even though this model is not directly applicable to in vivo systems as a standalone formulation, it can be applied to inform macroscopic metabolism-related parameters in the PBTK model. On the other hand, more experimental studies on arsenicals in human hepatocytes will substantially improve model structure and can help in characterizing inter-individual variability in arsenic metabolism. Currently, the Styblo et al. study  is the only study in the authors' knowledge that reports time course profiles of arsenic methylation in human hepatocytes. Furthermore, significant uncertainties exist in experimental data due to the limitations of widely used techniques such as hydride generation-atomic absorption spectroscopy (HG-AAS) and high performance liquid chromatography-inductively coupled plasma-mass spectrometry (HPLC-ICP-MS), where glutathione conjugated arsenic species ATG and MADG have been reported to be degraded to iAsIII and MMAIII during the speciation analysis in the bile of rats exposed to arsenic [64, 65].
This cellular-level TK model is based on an arsenic biotransformation pathway where arsenic-GSH adducts (ATG, MADG) are substrates for the respective methylation reactions [27, 28]. It should be pointed out that arsenic can be efficiently methylated even in the absence of GSH [49, 66], indicating that arsenic-GSH complexes need not be major species in the methylation of arsenic. On the other hand, the explicit consideration of arsenic-GSH complexes allows the description of a hysteresis behavior associated with methylation reactions and the stimulating role of GSH in these processes (Equations 7-8); so, this mechanism has been selected in this model. It should be noted that it is beyond the scope of this manuscript to comparatively evaluate the different arsenic biotransformation mechanisms.
Clearly it is, in principle, possible to incorporate into this cellular level TK model both the oxidative and reductive mechanisms as individual pathways. However, currently available experimental data are not adequate for estimating the relative contributions of each pathway. Development of improved experimental techniques for quantifying binding of arsenicals to GSH and thiol-containing proteins will allow the estimation of the relative contribution of each pathway. Since AS3MT coexists in hepatocytes with a number of competing elements that affect its action, its activity should be determined based on the availability of each of these elements. For instance, to study the effectiveness of the oxidative mechanism, it is possible to knock out GSH biosynthesis in hepatocytes by interfering with the activity of Glutamate-Cysteine Ligase (GCL) , and exposing them to various doses of arsenite. Such data sets can be used to estimate AS3MT activities along the two competing reaction pathways; this type of information is necessary in order to extend the mathematical formulation of the model described here to include both competing methylation pathways.
Parameter identification is an important issue in computational biology since most of the models involve more parameters than the available data. The TK model was parameterized using data on total arsenic of three species (iAs, MMA, DMA) and it was able to capture the modes of arsenic retention and methylation in human hepatocytes, but was not able to exactly capture the time-course profiles from the experimental data. In order to reduce the uncertainty associated with this issue, sensitivity analysis and testing were conducted as a means to identify the relative impact of each parameter on model predictions . Additional time-course data (either on intermediate species or under more exposure/dose conditions) can improve model performance, and can help obtain additional mechanistic insights into the dynamics of arsenicals in hepatocytes.
A cellular-level TK model was developed based on a recently proposed pathway of arsenic biotransformation. This model can describe uptake, retention and clearance of arsenicals in human hepatocytes using a semi-mechanistic approach. It highlights the key biological processes that influence arsenic metabolism by explicitly modelling the metabolic network of GSH-adducts formation . Moreover, comparison of the model structure and parameters with a rat-hepatocyte TK model  highlights the relative roles of different metabolic reactions in the methylation of arsenic. Ongoing work involves incorporating this cellular-level semi-mechanistic TK model as a module within a whole-body PBTK model of arsenic , in order to improve the PBTK model parameterization and its predictions .
This work was primarily supported by the USEPA-funded Environmental Bioinformatics and Computational Toxicology Center (ebCTC), Grant # GAD R 832721-010. Additional support was provided by the NIEHS sponsored UMDNJ Center for Environmental Exposures and Disease, Grant #: NIEHS P30ES005022.
- Cullen WR, Reimer KJ: Arsenic Speciation in the Environment. Chemical Reviews. 1989, 89: 713-764. 10.1021/cr00094a002.View ArticleGoogle Scholar
- ATSDR: Toxicological Profile for Arsenic. Atlanta: Agency for Toxic Substances and Disease Registry, US Department of Health and Human Services. 2007,Google Scholar
- Schuhmacher-Wolz U, Dieter HH, Klein D, Schneider K: Oral exposure to inorganic arsenic: evaluation of its carcinogenic and non-carcinogenic effects. Critical Reviews in Toxicology. 2009, 39: 271-298. 10.1080/10408440802291505View ArticlePubMedGoogle Scholar
- Guha Mazumder DN: Chronic arsenic toxicity & human health. Indian J Med Res. 2008, 128: 436-447.PubMedGoogle Scholar
- , : National primary drinking water regulations; arsenic and clarification to compliance and new source contaminants monitoring; final rule. Federal Register. 2001, 66: 6975-7066.Google Scholar
- Cohen SM, Arnold LL, Eldan M, Lewis AS, Beck BD: Methylated arsenicals: The implications of metabolism and carcinogenicity studies in rodents to human risk assessment. Critical Reviews in Toxicology. 2006, 36: 99-133. 10.1080/10408440500534230View ArticlePubMedGoogle Scholar
- Vahter M, Marafente E: Reduction and binding of arsenate in marmoset monkeys. Archives of Toxicology. 1985, 57: 119-124. 10.1007/BF00343121View ArticlePubMedGoogle Scholar
- Tseng CH: A review on environmental factors regulating arsenic methylation in humans. Toxicology and Applied Pharmacology. 2009, 235: 338-350. 10.1016/j.taap.2008.12.016View ArticlePubMedGoogle Scholar
- Kligerman AD, Tennant AH: Insights into the carcinogenic mode of action of arsenic. Toxicology and Applied Pharmacology. 2007, 222: 281-288. 10.1016/j.taap.2006.10.006View ArticlePubMedGoogle Scholar
- Dopp E, Hartmann LM, Florea AM, von Recklinghausen U, Pieper R, Shokouhi B, Rettenmeier AW, Hirner AV, Obe G: Uptake of inorganic and organic derivatives of arsenic associated with induced cytotoxic and genotoxic effects in Chinese hamster ovary (CHO) cells. Toxicology and Applied Pharmacology. 2004, 201: 156-165. 10.1016/j.taap.2004.05.017View ArticlePubMedGoogle Scholar
- Dopp E, Hartmann LM, von Recklinghausen U, Florea AM, Rabieh S, Zimmermann U, Shokouhi B, Yadav S, Hirner AV, Rettenmeier AW: Forced uptake of trivalent and pentavalent methylated and inorganic arsenic and its cyto-/genotoxicity in fibroblasts and hepatoma cells. Toxicological Sciences. 2005, 87: 46-56. 10.1093/toxsci/kfi218View ArticlePubMedGoogle Scholar
- Schwerdtle T, Walter I, Mackiw I, Hartwig A: Induction of oxidative DNA damage by arsenite and its trivalent and pentavalent methylated metabolites in cultured human cells and isolated DNA. Carcinogenesis. 2003, 24: 967-974. 10.1093/carcin/bgg018View ArticlePubMedGoogle Scholar
- Lin S, Del Razo LM, Styblo M, Wang CQ, Cullen WR, Thomas DJ: Arsenicals inhibit thioredoxin reductase in cultured rat hepatocytes. Chemical Research in Toxicology. 2001, 14: 305-311. 10.1021/tx0001878View ArticlePubMedGoogle Scholar
- Rossman TG: Mechanism of arsenic carcinogenesis: an integrated approach. Mutat Res. 2003, 533: 37-65. 10.1016/j.mrfmmm.2003.07.009View ArticlePubMedGoogle Scholar
- Liu ZJ, Sanchez MA, Jiang X, Boles E, Landfear SM, Rosen BP: Mammalian glucose permease GLUT1 facilitates transport of arsenic trioxide and methylarsonous acid. Biochemical and Biophysical Research Communications. 2006, 351: 424-430. 10.1016/j.bbrc.2006.10.054PubMed CentralView ArticlePubMedGoogle Scholar
- Liu ZJ, Shen J, Carbrey JM, Mukhopadhyay R, Agre P, Rosen BP: Arsenite transport by mammalian aquaglyceroporins AQP7 and AQP9. Proceedings of the National Academy of Sciences of the United States of America. 2002, 99: 6053-6058. 10.1073/pnas.092131899PubMed CentralView ArticlePubMedGoogle Scholar
- Tsukaguchi H, Weremowicz S, Morton CC, Hediger MA: Functional and molecular characterization of the human neutral solute channel aquaporin-9. American Journal of Physiology-Renal Physiology. 1999, 277: F685-F696.Google Scholar
- Drobna Z, Walton FS, Paul DS, Xing WB, Thomas DJ, Styblo M: Metabolism of arsenic in human liver: the role of membrane transporters. Archives of Toxicology. 2010, 84: 3-16. 10.1007/s00204-009-0499-7View ArticlePubMedGoogle Scholar
- Thomas DJ: Molecular processes in cellular arsenic metabolism. Toxicol Appl Pharmacol. 2007,Google Scholar
- Kala SV, Kala G, Prater CI, Sartorelli AC, Lieberman MW: Formation and urinary excretion of arsenic triglutathione and methylarsenic diglutathione. Chemical Research in Toxicology. 2004, 17: 243-249. 10.1021/tx0342060View ArticlePubMedGoogle Scholar
- Kala SV, Neely MW, Kala G, Prater CI, Atwood DW, Rice JS, Lieberman MW: The MRP2/cMOAT transporter and arsenic-glutathione complex formation are required for biliary excretion of arsenic. Journal of Biological Chemistry. 2000, 275: 33404-33408. 10.1074/jbc.M007030200View ArticlePubMedGoogle Scholar
- Kobayashi Y, Hayakawa T, Hirano S: Expression and activity of arsenic methyltransferase Cyt19 in rat tissues. Environmental Toxicology and Pharmacology. 2007, 23: 115-120. 10.1016/j.etap.2006.07.010View ArticlePubMedGoogle Scholar
- Vahter M, Concha G, Nermell B: Factors influencing arsenic methylation in humans. Journal of Trace Elements in Experimental Medicine. 2000, 13: 173-184. 10.1002/(SICI)1520-670X(2000)13:1<173::AID-JTRA18>3.0.CO;2-T.View ArticleGoogle Scholar
- Wood TC, Salavagionne OE, Mukherjee B, Wang LW, Klumpp AF, Thomae BA, Eckloff BW, Schaid DJ, Wieben ED, Weinshilboum RM: Human arsenic methyltransferase (AS3MT) pharmacogenetics - Gene resequencing and functional genomics studies. Journal of Biological Chemistry. 2006, 281: 7364-7373. 10.1074/jbc.M512227200View ArticlePubMedGoogle Scholar
- Drobna Z, Xing WB, Thomas DJ, Styblo M: shRNA silencing of AS3MT expression minimizes arsenic methylation capacity of HepG2 cells. Chemical Research in Toxicology. 2006, 19: 894-898. 10.1021/tx060076uPubMed CentralView ArticlePubMedGoogle Scholar
- Thomas DJ, Waters SB, Styblo M: Elucidating the pathway for arsenic methylation. Toxicology and Applied Pharmacology. 2004, 198: 319-326. 10.1016/j.taap.2003.10.020View ArticlePubMedGoogle Scholar
- Hayakawa T, Kobayashi Y, Cui X, Hirano S: A new metabolic pathway of arsenite: arsenic-glutathione complexes are substrates for human arsenic methyltransferase Cyt19. Archives of Toxicology. 2005, 79: 183-191. 10.1007/s00204-004-0620-xView ArticlePubMedGoogle Scholar
- Naranmandura H, Suzuki N, Suzuki KT: Trivalent arsenicals are bound to proteins during reductive methylation. Chemical Research in Toxicology. 2006, 19: 1010-1018. 10.1021/tx060053fView ArticlePubMedGoogle Scholar
- Waters SB, Devesa V, Del Razo LM, Styblo M, Thomas DJ: Endogenous reductants support the catalytic function of recombinant rat Cyt19, an arsenic methyltransferase. Chemical Research in Toxicology. 2004, 17: 404-409. 10.1021/tx0342161View ArticlePubMedGoogle Scholar
- Kobayashi M, Yamamoto M: Molecular mechanisms activating the Nrf2-Keap1 pathway of antioxidant gene regulation. Antioxidants & Redox Signaling. 2005, 7: 385-394. 10.1089/ars.2005.7.385View ArticleGoogle Scholar
- Li WG, Kong AN: Molecular Mechanisms of Nrf2-Mediated Antioxidant Response. Molecular Carcinogenesis. 2009, 48: 91-104. 10.1002/mc.20465PubMed CentralView ArticlePubMedGoogle Scholar
- Wang XJ, Sun Z, Chen WM, Li YJ, Villeneuve NF, Zhang DD: Activation of Nrf2 by arsenite and monomethylarsonous acid is independent of Keap1-C151: enhanced Keap1-Cul3 interaction. Toxicology and Applied Pharmacology. 2008, 230: 383-389. 10.1016/j.taap.2008.03.003PubMed CentralView ArticlePubMedGoogle Scholar
- He XQ, Chen MG, Lin GX, Ma Q: Arsenic induces NAD(P)H-quinone oxidoreductase I by disrupting the Nrf2 center dot Keap1 center dot CuI3 complex and recruiting Nrf2 center dot Maf to the antioxidant response element enhancer. Journal of Biological Chemistry. 2006, 281: 23620-23631. 10.1074/jbc.M604120200View ArticlePubMedGoogle Scholar
- Easterling MR, Styblo M, Evans MV, Kenyon EM: Pharmacokinetic modeling of arsenite uptake and metabolism in hepatocytes - Mechanistic insights and implications for further experiments. Journal of Pharmacokinetics and Pharmacodynamics. 2002, 29: 207-234. 10.1023/A:1020248922689View ArticlePubMedGoogle Scholar
- Tyson JJ, Chen KC, Novak B: Sniffers, buzzers, toggles and blinkers: dynamics of regulatory and signaling pathways in the cell. Current Opinion in Cell Biology. 2003, 15: 221-231. 10.1016/S0955-0674(03)00017-6View ArticlePubMedGoogle Scholar
- Miao ZF, Chang EE, Tsai FY, Yeh SC, Wu CF, Wu KY, Wang CJ, Tsou TC: Increased aquaglyceroporin 9 expression disrupts arsenic resistance in human lung cancer cells. Toxicology in Vitro. 2009, 23: 209-216. 10.1016/j.tiv.2008.11.011View ArticlePubMedGoogle Scholar
- Hodgkin AL, Huxley AF: A quantitative description of membrane current and its application to conduction and excitation in nerve. J Physiol. 1952, 117: 500-544.PubMed CentralView ArticlePubMedGoogle Scholar
- Kitchin KT, Wallace K: The role of protein binding of trivalent arsenicals in arsenic carcinogenesis and toxicity. Journal of Inorganic Biochemistry. 2008, 102: 532-539. 10.1016/j.jinorgbio.2007.10.021View ArticlePubMedGoogle Scholar
- Kitchin KT, Del Razo LM, Brown JL, Anderson WL, Kenyon EM: An integrated pharmacokinetic and pharmacodynamic study of arsenite action. 1. Heme oxygenase induction in rats. Teratogenesis Carcinogenesis and Mutagenesis. 1999, 19: 385-402. 10.1002/(SICI)1520-6866(1999)19:6<385::AID-TCM3>3.0.CO;2-V.View ArticleGoogle Scholar
- Shinkai Y, Sumi D, Fukami I, Ishii T, Kumagai Y: Sulforaphane, an activator of Nrf2, suppresses cellular accumulation of arsenic and its cytotoxicity in primary mouse hepatocytes. Febs Letters. 2006, 580: 1771-1774. 10.1016/j.febslet.2006.02.031View ArticlePubMedGoogle Scholar
- Vollrath V, Wielandt AM, Iruretagoyena M, Chianale J: Role of Nrf2 in the regulation of the Mrp2 (ABCC2) gene. Biochemical Journal. 2006, 395: 599-609. 10.1042/BJ20051518PubMed CentralView ArticlePubMedGoogle Scholar
- Abraham AK, Mager DE, Gao X, Li M, Healy DR, Maurer TS: Mechanism-Based Pharmacokinetic/Pharmacodynamic Model of Parathyroid Hormone-Calcium Homeostasis in Rats and Humans. Journal of Pharmacology and Experimental Therapeutics. 2009, 330: 169-178. 10.1124/jpet.109.152033View ArticlePubMedGoogle Scholar
- Sarangapani R, Teeguarden J, Plotzke KP, McKim JM, Andersen ME: Dose-response modeling of cytochrome P450 induction in rats by octamethylcyclotetrasiloxane. Toxicological Sciences. 2002, 67: 159-172. 10.1093/toxsci/67.2.159View ArticlePubMedGoogle Scholar
- El-Masri HA, Kenyon EM: Development of a human physiologically based pharmacokinetic (PBPK) model for inorganic arsenic and its mono- and di-methylated metabolites. J Pharmacokinet Pharmacodyn. 2008, 35: 31-68. 10.1007/s10928-007-9075-zView ArticlePubMedGoogle Scholar
- Mann S, Droz PO, Vahter M: A physiologically based pharmacokinetic model for arsenic exposure .2. Validation and application in humans. Toxicology and Applied Pharmacology. 1996, 140: 471-486. 10.1006/taap.1996.0244View ArticlePubMedGoogle Scholar
- Yu DH: A physiologically based pharmacokinetic model of inorganic arsenic. Regulatory Toxicology and Pharmacology. 1999, 29: 128-141. 10.1006/rtph.1999.1282View ArticlePubMedGoogle Scholar
- Monod J, Wyman J, Changeux JP: On the Nature of Allosteric Transitions: A Plausible Model. J Mol Biol. 1965, 12: 88-118. 10.1016/S0022-2836(65)80285-6View ArticlePubMedGoogle Scholar
- Frieden C: Kinetic aspects of regulation of metabolic processes. The hysteretic enzyme concept. J Biol Chem. 1970, 245: 5788-5799.PubMedGoogle Scholar
- Thomas DJ: Unraveling Arsenic-EFGlutathione Connections. Toxicological Sciences. 2009, 107: 309-311. 10.1093/toxsci/kfn257View ArticlePubMedGoogle Scholar
- Leslie EM, Haimeur A, Waalkes MP: Arsenic transport by the human multidrug resistance protein 1 (MRP1/ABCC1) - Evidence that a tri-glutathione conjugate is required. Journal of Biological Chemistry. 2004, 279: 32700-32708. 10.1074/jbc.M404912200View ArticlePubMedGoogle Scholar
- Styblo M, Del Razo LM, LeCluyse EL, Hamilton GA, Wang CQ, Cullen WR, Thomas DJ: Metabolism of arsenic in primary cultures of human and rat hepatocytes. Chemical Research in Toxicology. 1999, 12: 560-565. 10.1021/tx990050lView ArticlePubMedGoogle Scholar
- Gutkin BS, Dehaene S, Changeux JP: A neurocomputational hypothesis for nicotine addiction. Proceedings of the National Academy of Sciences of the United States of America. 2006, 103: 1106-1111. 10.1073/pnas.0510220103PubMed CentralView ArticlePubMedGoogle Scholar
- Drobna Z, Waters SB, Walton FS, LeCluyse EL, Thomas DJ, Styblo M: Interindividual variation in the metabolism of arsenic in cultured primary human hepatocytes. Toxicology and Applied Pharmacology. 2004, 201: 166-177. 10.1016/j.taap.2004.05.004View ArticlePubMedGoogle Scholar
- , : Simulation Environment for Uncertainty and Sensitivity Analysis, developed by the Joint Research Centre of the European Commission. Version 32. 2009,Google Scholar
- Weisz OA, Schnaar RL: Hepatocyte Adhesion to Carbohydrate-Derivatized Surfaces .1. Surface-Topography of the Rat Hepatic Lectin. Journal of Cell Biology. 1991, 115: 485-493. 10.1083/jcb.115.2.485View ArticlePubMedGoogle Scholar
- Dopp E, von Recklinghausen U, Hartmann LM, Stueckradt I, Pollok I, Rabieh S, Hao L, Nussler A, Katier C, Hirner AV, Rettenmeier AW: Subcellular distribution of inorganic and methylated arsenic compounds in human urothelial cells and human hepatocytes. Drug Metabolism and Disposition. 2008, 36: 971-979. 10.1124/dmd.107.019034View ArticlePubMedGoogle Scholar
- Chan K, Saltelli A, Tarantola S: Sensitivity analysis of model output: Variance-based methods make the difference. Proceedings of the 1997 Winter Simulation Conference. 1997,Google Scholar
- Saltelli A, Tarantola S, Chan KPS: A quantitative model-independent method for global sensitivity analysis of model output. Technometrics. 1999, 41: 39-56. 10.2307/1270993.View ArticleGoogle Scholar
- Andersen ME, Yang RSH, French CT, Chubb LS, Dennison JE: Molecular circuits, biological switches, and nonlinear dose-response relationships. Environmental Health Perspectives. 2002, 110: 971-978. 10.1289/ehp.110-a444PubMed CentralView ArticlePubMedGoogle Scholar
- Ferrell JE, Machleder EM: The biochemical basis of an all-or-none cell fate switch in Xenopus oocytes. Science. 1998, 280: 895-898. 10.1126/science.280.5365.895View ArticlePubMedGoogle Scholar
- Andersen ME, Eklund CR, Mills JJ, Barton HA, Birnbaum LS: A multicompartment geometric model of the liver in relation to regional induction of cytochrome P450s. Toxicology and Applied Pharmacology. 1997, 144: 135-144. 10.1006/taap.1996.8066View ArticlePubMedGoogle Scholar
- Krishna S, Jensen MH, Sneppen K: Minimal model of spiky oscillations in NF-kappa B signaling. Proceedings of the National Academy of Sciences of the United States of America. 2006, 103: 10840-10845. 10.1073/pnas.0604085103PubMed CentralView ArticlePubMedGoogle Scholar
- Ortiz JGM, Opoka R, Kane D, Cartwright IL: Investigating Arsenic Susceptibility from a Genetic Perspective in Drosophila Reveals a Key Role for Glutathione Synthetase. Toxicological Sciences. 2009, 107: 416-426. 10.1093/toxsci/kfn192View ArticlePubMedGoogle Scholar
- Munro KL, Mariana A, Klavins AI, Foster AJ, Lai B, Vogo S, Cai Z, Harris HH, Dillon CT: Microprobe XRF mapping and XAS investigations of the intracellular metabolism of arsenic for understanding arsenic-induced toxicity. Chemical Research in Toxicology. 2008, 21: 1760-1769. 10.1021/tx800128dView ArticlePubMedGoogle Scholar
- Cui X, Kobayashi Y, Hayakawa T, Hirano S: Arsenic speciation in bile and urine following oral and intravenous exposure to inorganic and organic arsenics in rats. Toxicological Sciences. 2004, 82: 478-487. 10.1093/toxsci/kfh265View ArticlePubMedGoogle Scholar
- Thomas DJ, Li JX, Waters SB, Xing WB, Adair BM, Drobna Z, Devesa V, Styblo M: Arsenic (+3 oxidation state) methyltransferase and the methylation of arsenicals. Experimental Biology and Medicine. 2007, 232: 3-13.PubMed CentralPubMedGoogle Scholar
- Dalton TP, Chen Y, Schneider SN, Nebert DW, Shertzer HG: Genetically altered mice to evaluate glutathione homeostasis in health and disease. Free Radical Biology and Medicine. 2004, 37: 1511-1526. 10.1016/j.freeradbiomed.2004.06.040View ArticlePubMedGoogle Scholar
- Gutenkunst RN, Waterfall JJ, Casey FP, Brown KS, Myers CR, Sethna JP: Universally sloppy parameter sensitivities in systems biology models. Plos Computational Biology. 2007, 3: 1871-1878. 10.1371/journal.pcbi.0030189View ArticlePubMedGoogle Scholar
- Clewell RA, Clewell HJ: Development and specification of physiologically based pharmacokinetic models for use in risk assessment. Regulatory Toxicology and Pharmacology. 2008, 50: 129-143. 10.1016/j.yrtph.2007.10.012View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.